Vertex Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	3,675	-535.6	3,620	3,322	2,342	2,712
Depreciation & Amortization	175.4	182	169.5	148.3	125.6	109.5
Other Amortization	25.2	25.2	11.8	-	-	-
Asset Writedown & Restructuring Costs	379	-	-	-	-	-
Loss (Gain) From Sale of Investments	19.4	57.7	0.6	149.1	-17.1	-311.9
Stock-Based Compensation	696.1	698.5	581.2	491.3	441.4	429.5
Other Operating Activities	-440.7	-405.6	-579.7	-321.6	-143.3	369.1
Change in Accounts Receivable	-178.9	-99.3	-84.1	-358.6	-274.7	-223.4
Change in Inventory	-594.3	-517.3	-322.9	-136.4	-92.8	-132
Change in Accounts Payable	6.9	49.5	48.7	120.8	31.9	51.3
Change in Other Net Operating Assets	-45.2	52.3	92.6	715	230.4	249.7
Operating Cash Flow	3,718	-492.6	3,537	4,130	2,644	3,254
Operating Cash Flow Growth	-	-	-14.35%	56.23%	-18.75%	107.32%
Capital Expenditures	-380.8	-297.7	-200.4	-204.7	-235	-259.8
Cash Acquisitions	-	-	-	-295.9	-	-
Sale (Purchase) of Intangibles	-	-187.7	-58	-	-	-
Investment in Securities	-1,059	-3,231	-2,852	227.3	-105.9	359.2
Other Investing Activities	-39.7	-54	-31	-47.8	-	-
Investing Cash Flow	-1,479	-3,770	-3,142	-321.1	-340.9	99.4
Long-Term Debt Issued	-	-	-	-	28.3	13.3
Total Debt Issued	-	-	-	-	28.3	13.3
Long-Term Debt Repaid	-	-33.6	-44.9	-85.5	-47	-42.3
Total Debt Repaid	-5.3	-33.6	-44.9	-85.5	-47	-42.3
Net Debt Issued (Repaid)	-5.3	-33.6	-44.9	-85.5	-18.7	-29
Issuance of Common Stock	108	114.6	134.6	186.3	102	264.9
Repurchase of Common Stock	-2,682	-1,582	-653.7	-172	-1,561	-739.4
Other Financing Activities	3.5	6.2	1.8	3.5	-	-1.8
Financing Cash Flow	-2,575	-1,495	-562.2	-67.7	-1,478	-505.3
Foreign Exchange Rate Adjustments	36.3	-42.6	26.9	-29.2	-13.4	20.6
Net Cash Flow	-300.3	-5,800	-139.7	3,712	811.2	2,868
Free Cash Flow	3,337	-790.3	3,337	3,925	2,409	2,994
Free Cash Flow Growth	-	-	-14.99%	62.97%	-19.55%	100.39%
Free Cash Flow Margin	28.47%	-7.17%	33.81%	43.95%	31.80%	48.24%
Free Cash Flow Per Share	12.92	-3.06	12.81	15.15	9.27	11.37
Cash Interest Paid	12.1	30.5	43.1	52.3	56.3	54.5
Cash Income Tax Paid	1,449	1,082	1,677	1,058	476.3	191.8
Levered Free Cash Flow	2,914	2,800	3,510	3,307	2,402	2,232
Unlevered Free Cash Flow	2,922	2,819	3,538	3,342	2,441	2,268
Change in Working Capital	-811.5	-514.8	-265.7	340.8	-105.2	-54.4

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.